So Far So Good
Vaximm Gets Positive Readout on Oral Cancer Vaccine VXM01
By Cormac Sheridan
Monday, February 11, 2013
Top-line data from a Phase I/II trial of Vaximm AG's oral cancer vaccine VXM01 in patients with advanced pancreatic cancer provide the first clinical indications that the vaccine can elicit an immune response.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.